<DOC>
	<DOCNO>NCT02996305</DOCNO>
	<brief_summary>The purpose study assess safety tolerability oral OV101 ( gaboxadol ) adult subject Angelman syndrome . In addition , several exploratory efficacy outcome measure investigate .</brief_summary>
	<brief_title>A Study Adults With Angelman Syndrome</brief_title>
	<detailed_description>Two dose schedule OV101 ( gaboxadol ) give daily twice daily dose assessed placebo .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Angelman Syndrome</mesh_term>
	<mesh_term>Gaboxadol</mesh_term>
	<criteria>Inclusion Criteria 1 . Age 18 49 year 2 . Diagnosis Angelman syndrome 3 . Receiving stable regimen concomitant medication least 4 week prior Baseline , able maintain throughout duration study 4 . Has caregiver capable providing informed consent behalf subject able attend schedule study visit 5 . Able ingest study medication 6 . Caregivers must agree post subject study information social medium Exclusion Criteria 1 . Unable perform study relate safety exploratory efficacy assessment , motor function 2 . Poorly controlled seizure activity 3 . Concomitant cardiovascular , respiratory , liver , renal , hematologic disease degree would limit participation study 4 . Pregnancy woman childbearing potential use acceptable method contraception 5 . Concomitant use minocycline , levodopa , zolpidem , zaleplon , eszopiclone , ramelteon , cannabinoid derivative , use investigational agent , device , and/or investigational procedure 4 week prior Baseline study 6 . Allergy OV101 excipients 7 . At increase risk harm self and/or others base investigator assessment 8 . Any condition reason opinion investigator make subject unsuitable enrollment 9 . Inability subject caregiver comply study requirement Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>